-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The salary status of pharmaceutical company CEOs is closely related to the company's performance in the year.
The overall performance of multinational pharmaceutical companies recovered last year, so the salary of most executives has increased
.
For example, the salaries of CEOs of Roche and Novartis, two multinational pharmaceutical companies, will increase in 2021
.
Specifically, Roche CEO Severin Schwan’s total compensation last year was 11.
49 million Swiss francs ($12.
48 million), an increase of 4% compared to 2020; Novartis CEO Vas Narasimhan received 11.
22 million Swiss francs ($12.
18 million) worth of compensation.
Compensation, an 8% increase from CHF 10.
38 million in 2020
.
For a long time, the salaries of CEOs of many large pharmaceutical companies have been at the forefront of the industry
.
According to public information, the salaries of CEOs of multinational pharmaceutical companies such as GSK and AstraZeneca in 2021 have exceeded US$10 million
.
Among them, the salary of GSK CEO Emma Walmsley has increased significantly with the "sales performance" in 2021, which has reached 11.
29 million US dollars (8.
2 million pounds), a year-on-year increase of 17%
.
In addition, Novartis CEO Vas Narasimhan's compensation in 2021 will be 11.
22 million Swiss francs (12.
28 million US dollars), also an increase of 5% year-on-year
.
There is also GlaxoSmithKline's Emma Walmsley's 2021 salary of $11.
29 million (£8.
2 million), an increase of 17% year-on-year; AstraZeneca's Pascal Soriot also has an on-site salary of $19.
08 million (£13.
86 million) in 2021
.
Of course, there are ups and downs, and Johnson & Johnson recently released its 2021 executive compensation report
.
Chief Executive Officer (CEO) Alex Gorsky's total compensation last year was $26.
74 million, down 9.
6% from 2021
.
However, even if it falls, Alex Gorsky's salary is still at the forefront among the CEOs of many multinational pharmaceutical companies
.
There is also a certain gap between the salary increases of the CEOs of Roche and Novartis, two multinational pharmaceutical companies
.
Returning to local pharmaceutical companies, the salaries of relevant medical personnel are actually getting more and more considerable
.
Previously, some media ranked the executive compensation of listed technology companies and the annual salary of executives.
Among the top 20 executive compensation lists, there are 7 pharmaceutical companies
.
Among the top 50 annual salary of executives, 30 people from the pharmaceutical industry are also on the list, from 18 companies
.
It can be seen from the above that in many industries, pharmaceutical companies are actually very generous in their compensation for executives
.
Taking BeiGene as an example, from 2018 to 2020, the pre-tax salaries of BeiGene directors, senior managers and core technicians have been increasing, with 175 million yuan, 257 million yuan, and 314 million yuan respectively
.
It is worth mentioning that its co-founder, chairman and CEO Ou Leiqiang has an annual salary of 101 million yuan; in addition, its co-founder and chairman of the scientific advisory board Wang Xiaodong has an annual salary of 41 million yuan
.
It is understood that the rise or fall of executive compensation of pharmaceutical companies has a certain relationship with their performance
.
From the above point of view, the performance of a large number of pharmaceutical companies is continuing to improve
.
Under the continuous improvement of performance, the increase in executive compensation is to be expected
.
It is worth noting that the demand for talents in the domestic pharmaceutical industry is still very strong
.
Recently, companies such as BeiGene, Menarini, Sanofi, and Sino-US East China have been vigorously recruiting regional managers, pharmaceutical representatives and other positions.
Against this background, the industry expects that more and more corporate executives and employees will be employed in the future.
Staff, wages will continue to increase
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The overall performance of multinational pharmaceutical companies recovered last year, so the salary of most executives has increased
.
For example, the salaries of CEOs of Roche and Novartis, two multinational pharmaceutical companies, will increase in 2021
.
Specifically, Roche CEO Severin Schwan’s total compensation last year was 11.
49 million Swiss francs ($12.
48 million), an increase of 4% compared to 2020; Novartis CEO Vas Narasimhan received 11.
22 million Swiss francs ($12.
18 million) worth of compensation.
Compensation, an 8% increase from CHF 10.
38 million in 2020
.
For a long time, the salaries of CEOs of many large pharmaceutical companies have been at the forefront of the industry
.
According to public information, the salaries of CEOs of multinational pharmaceutical companies such as GSK and AstraZeneca in 2021 have exceeded US$10 million
.
Among them, the salary of GSK CEO Emma Walmsley has increased significantly with the "sales performance" in 2021, which has reached 11.
29 million US dollars (8.
2 million pounds), a year-on-year increase of 17%
.
In addition, Novartis CEO Vas Narasimhan's compensation in 2021 will be 11.
22 million Swiss francs (12.
28 million US dollars), also an increase of 5% year-on-year
.
There is also GlaxoSmithKline's Emma Walmsley's 2021 salary of $11.
29 million (£8.
2 million), an increase of 17% year-on-year; AstraZeneca's Pascal Soriot also has an on-site salary of $19.
08 million (£13.
86 million) in 2021
.
Of course, there are ups and downs, and Johnson & Johnson recently released its 2021 executive compensation report
.
Chief Executive Officer (CEO) Alex Gorsky's total compensation last year was $26.
74 million, down 9.
6% from 2021
.
However, even if it falls, Alex Gorsky's salary is still at the forefront among the CEOs of many multinational pharmaceutical companies
.
There is also a certain gap between the salary increases of the CEOs of Roche and Novartis, two multinational pharmaceutical companies
.
Returning to local pharmaceutical companies, the salaries of relevant medical personnel are actually getting more and more considerable
.
Previously, some media ranked the executive compensation of listed technology companies and the annual salary of executives.
Among the top 20 executive compensation lists, there are 7 pharmaceutical companies
.
Among the top 50 annual salary of executives, 30 people from the pharmaceutical industry are also on the list, from 18 companies
.
It can be seen from the above that in many industries, pharmaceutical companies are actually very generous in their compensation for executives
.
Taking BeiGene as an example, from 2018 to 2020, the pre-tax salaries of BeiGene directors, senior managers and core technicians have been increasing, with 175 million yuan, 257 million yuan, and 314 million yuan respectively
.
It is worth mentioning that its co-founder, chairman and CEO Ou Leiqiang has an annual salary of 101 million yuan; in addition, its co-founder and chairman of the scientific advisory board Wang Xiaodong has an annual salary of 41 million yuan
.
It is understood that the rise or fall of executive compensation of pharmaceutical companies has a certain relationship with their performance
.
From the above point of view, the performance of a large number of pharmaceutical companies is continuing to improve
.
Under the continuous improvement of performance, the increase in executive compensation is to be expected
.
It is worth noting that the demand for talents in the domestic pharmaceutical industry is still very strong
.
Recently, companies such as BeiGene, Menarini, Sanofi, and Sino-US East China have been vigorously recruiting regional managers, pharmaceutical representatives and other positions.
Against this background, the industry expects that more and more corporate executives and employees will be employed in the future.
Staff, wages will continue to increase
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
